Table 6.
The association between baseline serum alkaline phosphatase (ALP) and new-onset diabetes, with further adjustment for AST, ALT and GGT
| ALP, IU/L | N | No. of events (%) | Crude model | Adjusted model* | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value† | OR (95% CI) | P value† | |||
| Continuous, per SD increment | 14,393 | 1549 (10.8) | 1.07 (1.02,1.13) | 0.007 | 1.06 (1.00,1.13) | 0.045 |
| Quartiles | ||||||
| Q1 (< 79) | 3486 | 343 (9.8) | 1.00 (ref.) | 1.00 (ref.) | ||
| Q2 (79- < 96) | 3623 | 381 (10.5) | 1.08 (0.92,1.26) | 0.346 | 1.08 (0.92,1.28) | 0.327 |
| Q3 (96- < 116) | 3577 | 390 (10.9) | 1.12 (0.96,1.31) | 0.143 | 1.13 (0.96,1.33) | 0.148 |
| Q4 (≥ 116) | 3707 | 435 (11.7) | 1.22 (1.05,1.42) | 0.010 | 1.23 (1.03,1.46) | 0.020 |
| P for trend | 0.009 | 0.019 | ||||
ALP serum alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, eGFR estimated glomerular filtration rate, GGT gamma glutamyl transpeptidase, OR odds ratio, SD standard deviations, SBP systolic blood pressure
*Adjusted for age, sex, study center, treatment group, body mass index (BMI), smoking, alcohol drinking, family history of diabetes, SBP, fasting glucose (FG), total cholesterol (TC), triglycerides (TG), eGFR, folate, total homocysteine and the use of antihypertensive drugs, AST, ALT, GGT at baseline, as well as time-averaged SBP during the treatment period
†In comparison with the first quartile